title: B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma.
abstract: B7-H1 is a member of the B7 family that inhibits the function of T-cells through its receptor programmed death-1 (PD-1). We examined B7-H1 expression in anaplastic large cell lymphoma (ALCL) and Hodgkin lymphoma (HL) and found that it was constitutively expressed in both clinical samples and cell lines. In anaplastic lymphoma kinase-positive (ALK(+)) ALCL cells, B7-H1 expression was suppressed by the blocking of extracellular signal-regulated kinase (ERK) signaling and upregulated by the augmentation of ERK activity by phorbol 13-myristate 12-acetate stimulation, suggesting that B7-H1 expression is regulated by ERK signaling pathway in ALCL. ERK is one of the downstream mediators of nucleophosmin (NPM)/ALK signaling in ALK(+)ALCL, and pharmacological inhibition of ALK was shown to dephosphorylate ERK and down-regulate B7-H1. The involvement of NPM/ALK in B7-H1 expression was also demonstrated by introducing the construct into human non-ALCL lymphoid cell lines, which resulted in B7-H1 expression. In the case of HL, B7-H1 expression was shown to be dependent on the ERK and p38 mitogen-activated protein kinase (MAPK) signaling pathways. These results suggest that B7-H1 expression is controlled by common ERK signaling pathways in ALCL and HL cells. Our findings provide a potentially effective immunotherapeutic strategy for these B7-H1-expressing tumors.
authors.affiliation: Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto, Japan.
authors.forename: Ryo
authors.initials: R
authors.lastname: Yamamoto
authors.forename: Momoko
authors.initials: M
authors.lastname: Nishikori
authors.forename: Masaharu
authors.initials: M
authors.lastname: Tashima
authors.forename: Tomomi
authors.initials: T
authors.lastname: Sakai
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Ichinohe
authors.forename: Akifumi
authors.initials: A
authors.lastname: Takaori-Kondo
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Ohmori
authors.forename: Takashi
authors.initials: T
authors.lastname: Uchiyama
mesh_terms: D015703:Antigens, CD / Q000032:analysis* / Q000502:physiology; D060890:B7-H1 Antigen; D045744:Cell Line, Tumor; D048049:Extracellular Signal-Regulated MAP Kinases / Q000502:physiology*; D006689:Hodgkin Disease / Q000378:metabolism*; D006801:Humans; D017728:Lymphoma, Large-Cell, Anaplastic / Q000378:metabolism*; D020935:MAP Kinase Signaling System / Q000502:physiology*; D020929:Mitogen-Activated Protein Kinase Kinases / Q000502:physiology*; D011505:Protein-Tyrosine Kinases / Q000502:physiology; D050796:STAT3 Transcription Factor / Q000502:physiology
chemical_list: D015703:Antigens, CD; D060890:B7-H1 Antigen; C423236:CD274 protein, human; D050796:STAT3 Transcription Factor; C494086:STAT3 protein, human; C107023:p80(NPM-ALK) protein; D011505:Protein-Tyrosine Kinases; D048049:Extracellular Signal-Regulated MAP Kinases; D020929:Mitogen-Activated Protein Kinase Kinases
references.citation: Oncogene. 1994 Jun;9(6):1567-74
references.pmid: 8183550
references.citation: Oncogene. 2003 Aug 21;22(35):5399-407
references.pmid: 12934099
references.citation: Blood. 2003 Apr 1;101(7):2789-96
references.pmid: 12456498
references.citation: FEBS Lett. 2006 Feb 6;580(3):755-62
references.pmid: 16413538
references.citation: Blood. 2002 Mar 15;99(6):2100-6
references.pmid: 11877285
references.citation: Blood. 2008 Mar 15;111(6):3220-4
references.pmid: 18203952
references.citation: Annu Rev Immunol. 2005;23:515-48
references.pmid: 15771580
references.citation: Nat Rev Cancer. 2008 Jan;8(1):11-23
references.pmid: 18097461
references.citation: Nat Med. 2005 Jun;11(6):623-9
references.pmid: 15895073
references.citation: Science. 1994 Mar 4;263(5151):1281-4
references.pmid: 8122112
references.citation: Blood. 2000 Dec 15;96(13):4319-27
references.pmid: 11110708
references.citation: Nat Rev Cancer. 2009 Jan;9(1):15-27
references.pmid: 19078975
references.citation: Oncogene. 2003 Aug 11;22(33):5108-21
references.pmid: 12910248
references.citation: Mol Cell Biol. 1998 Dec;18(12):6951-61
references.pmid: 9819383
references.citation: Cancer. 2003 Aug 1;98(3):458-67
references.pmid: 12879461
references.citation: Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20852-7
references.pmid: 19088198
references.citation: Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):9964-9
references.pmid: 16766651
references.citation: Br J Haematol. 1990 Feb;74(2):161-8
references.pmid: 2156548
references.citation: Blood. 1988 Jul;72(1):234-40
references.pmid: 3260522
references.citation: Blood. 2007 Nov 1;110(9):3374-83
references.pmid: 17690253
references.citation: Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7
references.pmid: 12218188
references.citation: Blood. 2005 Jan 15;105(2):827-9
references.pmid: 15374880
references.citation: Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17174-9
references.pmid: 15569934
references.citation: Nat Rev Immunol. 2004 May;4(5):336-47
references.pmid: 15122199
references.citation: Oncogene. 2007 Feb 8;26(6):813-21
references.pmid: 16909118
references.citation: Leukemia. 2009 Feb;23(2):375-82
references.pmid: 18830259
references.citation: Nat Rev Immunol. 2008 Jun;8(6):467-77
references.pmid: 18500231
references.citation: Lab Invest. 2005 Dec;85(12):1544-54
references.pmid: 16170336
references.citation: Blood. 2000 Aug 15;96(4):1605-7
references.pmid: 10942417
references.citation: Cancer Res. 2005 Sep 1;65(17):7628-34
references.pmid: 16140928
references.citation: Nat Med. 2002 Aug;8(8):793-800
references.pmid: 12091876
references.citation: Oncogene. 2002 Feb 7;21(7):1038-47
references.pmid: 11850821
references.citation: Blood. 2007 Jul 1;110(1):296-304
references.pmid: 17363736
references.citation: Clin Cancer Res. 2005 Apr 15;11(8):2947-53
references.pmid: 15837746
references.citation: Science. 2004 Aug 20;305(5687):1160-3
references.pmid: 15326357
references.citation: Nat Med. 2007 Jan;13(1):84-8
references.pmid: 17159987